Alzheimer's disease: Molecular concepts and therapeutic targets

Naturwissenschaften

Volumn 88, Issue 6, 2001, Pages 261-267

  Fassbender, K ^a   Masters, C ^b   Beyreuther, K ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

DISEASE;

ALZHEIMER DISEASE; ASSOCIATION CORTEX; BASAL GANGLION; FAMILIAL DISEASE; GENE MUTATION; GENOTYPE; LIMBIC SYSTEM; MOLECULAR DYNAMICS; PATHOPHYSIOLOGY; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; HUMANS; MEMBRANE PROTEINS; MUTATION; PRESENILIN-1; PRESENILIN-2;

EID: 0034896748     PISSN: 00281042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001140100237     Document Type: Review

References (86)

1. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
2. Neurochemical correlates of dementia severity in Alzheimer's disease: Relative importance of the cholinergic deficits
3. Alpha-2 macroglobulin is genetically associated with Alzheimer's disease
4. TNF alpha plus IFN gamma induce the production of Alzheimer-amyloid peptides and decrease the secretion of APPs
5. Neurotransmitter related enzymes and indices of hypoxia in senile dementia and other abiotrophies
6. Perlecan binds to the β-amyloid proteins (Aβ) of Alzheimer's Disease, accelerates Aβ fibril formation and maintains Aβ fibril stability
7. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production
8. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
9. Inflammatory mechanisms in Alzheimer's disease: Inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists
10. Alzheimer's A beta (1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2 N cells
11. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
12. Protective effects apolipoprotein E type 2 allele for late onset Alzheimer disease
13. Deficiency of presenilin-1 inhibits the normal cleavage of the transmembrane domain of amyloid precursor protein
14. Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease
15. The US economic and social costs of Alzheimer's disease revisited
16. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported
17. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo
18. Abeta modulation: The next generation of AD therapeutics
19. Effects of sulfate ions on Alzheimer β/A4 peptide assemblies: Implications for amyloid fibril-proteoglycan interactions
20. The role of cholesterol in the biosynthesis of beta-amyloid
21. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein
22. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity
23. Cholinesterase inhibitors for Alzheimer disease therapy: Past, present and future
24. Does Alzheimer disease tilt the scales of amyloid degradation versus accumulation?
25. Low concentrations of estradiol reduce beta-amyloid (25-35)-induced toxicity, lipid peroxydation and glucose utilization in human SK-N-SH neuroblastoma cells
26. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer Disease
27. Proteoglycan-mediated inhibition of A beta proteolysis: A potential cause of senile plaque accumulation
28. The presenilin genes and early dementia
29. Targeting of cell-surface β-amyloid precursor protein to lysosomes: Alternative processing into amyloid-bearing fragments
30. Distinct sites of intracellular production for Alzheimer's disease Aβ40/42 amyloid peptides
31. Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS
32. Age-specific incidence of Alzheimer's disease in a community population
33. Estrogen replacement therapy for the prevention and treatment of Alzheimer's disease
34. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial
35. Correlative memory deficits, Aβ-elevation and amyloid plaques in transgenic mice
36. Subacute NO generation induced by Alzheimer's β-amyloid in the living brain: Reversal by inhibition of the inducible NO synthase
37. Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression
38. Statins and the risk of dementia
39. Diffusible, non-fibrillar ligands derived from Abetal-42 are potent central nervous system neurotoxins
40. The E280 A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology
41. Exploring the etiology of Alzheimer disease using molecular genetics
42. A familial Alzheimer's disease locus on chromosome 1
43. Interleukin-1 beta and tumor necrosis factor-alpha induce expression of alpha-1-antichymotrypsin in human astrocytoma cells by activation of nuclear factor-kappa B
44. Neurocytopathic effects of beta-amyloid stimulated monocytes: A potential mechanism for central nervous system damage in Alzheimer disease
45. Plasma 24S-hydroxycholsterol (cerebrosterol) is increased in Alzheimer and vascular demented patients
46. Amyloid-associated proteins al-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments
47. Oxidative alterations in Alzheimer's disease
48. Alzheimer's disease
49. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
50. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease
51. Activation of microglial cells by beta-amyloid protein and interferon-gamma
52. Estrogen replacement therapy for treatment of mild to moderate Alzheimer Disease: A randomized controlled trial
53. Estrogen replacement therapy and risk of Alzheimer disease
54. Apolipoprotein E in animals of CNS injury and in Alzheimer's disease
55. Clinical trial of indomethacin in Alzheimer's disease
56. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: The Alzheimer's disease Cooperative Study
57. Apolipo-protein E4 allele distribution in late-onset Alzheimer's disease and in other amyloid-forming diseases
58. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14
59. Chromosome 14 and late-onset familial Alzheimer's disease (FAD)
60. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
61. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
62. Transthyretin sequesters amyloid protein and prevents amyloid formation
63. Secondary structure of amyloid β peptide correlates with neurotoxic activity in vitro
64. Amyloidogenic processing of the human amyloid precursor in primary cultures of rat hippocampal neurons
65. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons
66. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's Disease
67. Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease
68. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin and versican) to the β-amyloid protein of Alzheimer's disease
69. Identification in immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer's disease
70. Amyloid-beta aggregation: Selective inhibition of aggregation in mixtures of amyloid with different chain lengths
71. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy
72. Human apolipoprotein E isoform-specific differences in neuronal sprouting in organotypic hippocampal culture
73. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP): Evidence that LRP contributes to the pathogenesis of Alzheimer's disease
74. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
75. Franctionation and characterization of oligomeric proto-fibrillar and fibrillar forms of beta-amyloid peptide
76. Formation of stable complexes between two Alzheimer's disease gene products: Presenilin-2 and β-amyloid precursor protein
77. Beta-protein fibrillogenesis and neuritic plaques
78. Apolipoprotein E: Binding to soluble Alzheimer's beta-amyloid
79. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
80. Nongenomic actions of estrogen in the brain: Physiological significance and cellular mechanisms
81. Estrogen reduces neuronal generation of Alzheimers β-amyloid peptides
82. An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease
83. A century of cognitive decline
84. Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides
85. Cyclooxygenase-1 in human Alzheimer's and control brain: Quantitative analysis of expression by microglia and CA3 hippocampal neurons
86. Amyloid beta vaccination: Reduced plaques and improved cognition